In what has been hailed as a “breakthrough” and a “game changer,” a pricing agreement between the Bill and Melinda Gates Foundation and two generic drug companies will result in significant savings in the cost of antiretrovirals (ARVs). As a result of the agreement, starting in 2018 a state-of-the-art fixed dose combination ARV regimen will be available in 92 developing nations at a maximum cost of $75 per patient per year.
As GFO reported a few weeks ago, Zimbabwe submitted a TB/HIV funding request for $629 million in Window 1 of the current funding cycle. The $629 million request consisted of $432 million that was within Zimbabwe’s allocation, and $197 million for a prioritized above-allocation request (PAAR).
In January 2017, the Ministry of Finance of the Russian Federation rejected a request to allocate $1.2 billion over four years for the response to HIV, citing “a lack of federal funds.” The Ministry of Health had asked for the funds in order to implement the National AIDS Strategy 2017-2020.
An audit into grants to Mozambique undertaken by the Office of the Inspector General has concluded that both grant implementation arrangements and supply chain controls and assurance mechanisms “need significant improvement.”
“Needs significant improvement” is the second lowest rating in the OIG’s four tier rating scheme. The four tiers are effective; partially effective; needs significant improvement; and ineffective.
Advocacy for increased domestic funding led by CSOs and PRs, and strongly underpinned by the Global Fund’s conditions put to the government of Ukraine, has achieved outstanding results. Communities, empowered by the Global Fund, have been able to partner with the Ministry of Health.
AHF and researchers call for more transparency in UNAIDS’ estimates of the numbers of people on ARVs
The AIDS Healthcare Foundation (AHF), a Los Angeles-based AIDS service and activist organization with a global reach, has called for more transparency and accountability in the way UNAIDS estimates the number of people living with HIV/AIDS who are on life-saving antiretroviral treatment.
Among the grants approved by the Board in August (see GFO article) were four regional programs which received $25 million. The Board was acting on recommendations of the Technical Review Panel (TRP) and the Grants Approvals Committee (GAC). This article provides a summary of the some of the comments made by the GAC concerning the regional programs.
On 3 August 2016, the Board approved additional funding of $37 million to ensure that all essential services for a shortened HIV grant to Uganda can be provided through to 31 December 2017. The money will come from the $700 million which the Fund has identified as being available for portfolio optimization. The Board was acting on recommendations of the Technical Review Panel (TRP) and the Grant Approvals Committee (GAC).
There was praise for the bold goals in the political declaration adopted by the 193-national General Assembly at the United Nations High-Level Meeting on Ending AIDS on 8-10 June, but there was also widespread condemnation of the decision to include only limited references in the declaration to those most at ris